EVT 101

Drug Profile

EVT 101

Alternative Names: ENS 101; EVT101

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Roche
  • Developer Evotec AG
  • Class Antidementias; Antiparkinsonians
  • Mechanism of Action NR2B N-Methyl-D-Aspartate antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Major depressive disorder

Most Recent Events

  • 14 May 2014 Janssen plans to continue development of EVT 101 for Major depressive disorder
  • 17 Dec 2012 EVT 101 (including other NR2B selective NMDA antagonists) licensed to Janssen Pharmaceuticals worldwide for Major depressive disorder
  • 08 Sep 2011 Evotec Neurosciences GmbH terminates phase II trial in treatment-resistant Major depressive disorder in USA (NCT01128452)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top